Tiragolumab

TERMINATED · PHASE1, PHASE2 · Carcinoma, Hepatocellular

Study was closed early as the sponsor decided not to continue development of certain treatment combinations.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.